On the evening of March 4, By-Health Co.Ltd(300146) ( By-Health Co.Ltd(300146) . SZ) released the annual performance report for 2021.
The financial report shows that By-Health Co.Ltd(300146) achieved a revenue of 7.431 billion yuan last year, with a year-on-year increase of 21.93%. Excluding Maiyou’s consolidated statement, the comparable growth rate is 15.38%, lower than the expectation at the beginning of the year; The net profit attributable to shareholders of listed companies was 1.754 billion yuan, an increase of 15.07% over the same period last year; The net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was 1.54 billion yuan, a year-on-year increase of 34.59%.
Among them, the main brand ” By-Health Co.Ltd(300146) ” achieved a revenue of 4.445 billion yuan, a year-on-year increase of 24.36%; The joint care brand “jianliduo” achieved a revenue of 1.408 billion yuan, a year-on-year increase of 7.46%; The revenue of “life space” Chinese products was 184 million yuan, a year-on-year increase of 36.33%.
By channel, the revenue from offline channels accounted for about 64.29% of the domestic revenue of By-Health Co.Ltd(300146) last year, with a year-on-year increase of 8.58%; Online channel revenue increased by 45.88% year-on-year. According to the financial report, during the reporting period, the company fully launched the digitization of the whole marketing chain, promoted the upgrading and deployment of digital operation analysis tools, continued to build e-commerce digitization, super supply chain and other projects, and promoted the digitization of the whole link.
In terms of overseas business, LSG achieved an operating revenue of 659 million yuan, a year-on-year increase of 16.2% By-Health Co.Ltd(300146) believes that due to the dual impact of the decline in agency purchase and tourist purchase caused by the closure of the Australian epidemic, the local sales in Australia in the reporting period increased slightly compared with the same period last year.
With the release of the annual report, Liang Yunchao, chairman of By-Health Co.Ltd(300146) board of directors, proposed in a letter to shareholders that he hoped to preliminarily complete the transformation of strong technology-based enterprises in another eight years. He said, “we hope to launch an original high-tech heavy-duty product developed by us every two or three years in the future, which can truly bring incremental value to the health of consumers.”
According to Liang Yunchao, in the future, the company will focus on three aspects to realize the transformation to a strong science and technology enterprise. One is to implement the “scientific nutrition” strategy to create the core driving force of differentiated competitive advantage. Next, the “scientific nutrition” strategy will be embodied in three aspects: the research and development of proprietary raw materials and formulas, the research and development of new functional and heavy-duty products, and forward-looking basic research results such as registration, anti-aging and precision nutrition.
It is not difficult to find that By-Health Co.Ltd(300146) will focus on scientific research in the future. According to Liang Yunchao, Shanghai Research Center and AI research center of By-Health Co.Ltd(300146) nutrition and Health Research Institute will be established this year to further strengthen the product scientific and technological power of “high-precision and top” heavy function health food.
According to Euromonitor data, the total scale of China’s vitamin and dietary supplement industry in 2021 was 189.2 billion yuan, an increase of 6.60% over the previous year. Last year, By-Health Co.Ltd(300146) in China’s vitamin and dietary supplement industry, the market share was 10.3%, ranking first, and the market share ranked second and third was 6% and 5% respectively.
On the same day, By-Health Co.Ltd(300146) announced the annual dividend plan for 2021. Based on 1.7 billion shares of capital stock, cash dividends of 7 yuan (including tax) were distributed to all shareholders for every 10 shares, with a total cash dividend of 1.19 billion yuan.
